PREDNISONE PULSE THERAPY FOR REFRACTORY MYELOMA

  • 1 January 1983
    • journal article
    • research article
    • Vol. 62  (3) , 572-577
Abstract
The utility of vindesine and a frequent prednisone schedule was evaluated in 70 patients with refractory meyloma. No patient responded to vindesine alone, but about 1/4 achieved significant tumor reductions from intermittent high-dose prednisone, either alone or in combination with vindesine; 47% responded when prednisone pulses were combined with vincristine and doxorubicin, providing the best results yet achieved in the patients with refractory myeloma. In responding patients, remissions were of excellent quality and survival was prolonged significantly. The results support the utility of a more frequent corticosteroid schedule with increased doxorubicin dose in patients with advanced and resistant multiple myeloma.